Btk Inhibitor Compounds Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, inflammatory conditions, and certain cancers, particularly those involving B-cell proliferative disorders and thromboembolic disorders, lack effective and minimally invasive therapeutic options that target Bruton's tyrosine kinase (Btk) signaling pathways effectively.
Innovation Solution
Development of kinase inhibitor compounds, specifically Btk inhibitors, which are synthesized to inhibit Btk activity and are formulated into pharmaceutical compositions for administration, targeting Btk and other tyrosine kinases with a cysteine residue for therapeutic benefit in diseases such as autoimmune diseases, inflammatory conditions, and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for autoimmune diseases and inflammatory conditions, then broad therapeutic effects are achieved, but selective targeting of Btk signaling pathways is insufficient
Solution Approach 1:
The patent applies local quality by designing kinase inhibitors with specific molecular structures that selectively bind to and inhibit only certain kinases (such as Btk, Itk, Tec) while leaving other kinases unaffected. This is achieved through tailored chemical moieties that recognize specific kinase active sites, providing localized and selective therapeutic action on target pathways without broad-spectrum interference.
Solution Approach 2:
The kinase inhibitors act as intermediary molecules that mediate between the disease state and therapeutic outcome by specifically blocking Btk signaling pathways. These small molecule intermediaries interfere with the abnormal kinase activity in autoimmune and inflammatory conditions, translating the therapeutic intent into selective molecular inhibition of pathogenic signaling.
2Adaptability or versatility
If broad-spectrum kinase inhibition is used, then multiple signaling pathways are targeted, but off-target effects and side effects increase
Solution Approach 1:
The patent employs local quality by creating kinase inhibitors with differentiated molecular structures that provide selectivity for specific kinase families. Each inhibitor is designed with particular chemical features that match the binding pockets of target kinases (Btk, Itk, Tec) while avoiding off-target binding, thus achieving multi-pathway targeting without the harmful broad-spectrum effects of non-selective inhibitors.
Solution Approach 2:
The patent applies parameter changes by systematically modifying molecular parameters of kinase inhibitors (such as substituent groups, ring structures, and linker lengths) to optimize selectivity for specific kinases. By adjusting these chemical parameters, the inhibitors achieve desired specificity profiles that target multiple pathological pathways while minimizing off-target effects through precise structural-tactivity relationship optimization.
Data Source
AI summary
Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.